214 related articles for article (PubMed ID: 15243533)
21. Treprostinil for pulmonary hypertension.
Vachiéry JL; Naeije R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
[TBL] [Abstract][Full Text] [Related]
22. Bosentan: new preparation. Pulmonary hypertension: an option before epoprostenol infusion.
Prescrire Int; 2005 Apr; 14(76):47-50. PubMed ID: 15875338
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous hypersensitivity and eosinophilia associated with treprostinil.
Das A; Shabbir A; Sehgal S; Highland KB
Pulm Pharmacol Ther; 2015 Dec; 35():17-8. PubMed ID: 26407925
[No Abstract] [Full Text] [Related]
24. Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study.
Bendayan D; Shitrit D; Kramer MR
Respirology; 2008 Nov; 13(6):916-8. PubMed ID: 18811891
[TBL] [Abstract][Full Text] [Related]
25. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
[TBL] [Abstract][Full Text] [Related]
26. Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease.
Zaidi AN; Dettorre MD; Ceneviva GD; Thomas NJ
Pediatr Pulmonol; 2005 Sep; 40(3):265-9. PubMed ID: 15830393
[TBL] [Abstract][Full Text] [Related]
27. Treprostinil: new drug. Pulmonary artery hypertension: just another (disappointing) prostacycline analogue.
Prescrire Int; 2006 Oct; 15(85):177-9. PubMed ID: 17128524
[TBL] [Abstract][Full Text] [Related]
28. Living-donor lobar lung transplantation for pulmonary arterial hypertension after failure of epoprostenol therapy.
Date H; Kusano KF; Matsubara H; Ogawa A; Fujio H; Miyaji K; Okazaki M; Yamane M; Toyooka S; Aoe M; Sano Y; Hanazaki M; Goto K; Kasahara S; Sano S; Ohe T
J Am Coll Cardiol; 2007 Aug; 50(6):523-7. PubMed ID: 17678735
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results].
Jiménez López-Guarch C; Escribano Subias P; Tello de Meneses R; Delgado Jiménez JF; Sadia Pérez D; Velázquez Martín MT; Gómez Sánchez MA; Sáenz de la Calzada C
Rev Esp Cardiol; 2004 Oct; 57(10):946-51. PubMed ID: 15469792
[TBL] [Abstract][Full Text] [Related]
30. Low complication rates with totally implantable access port use in epoprostenol treatment of pulmonary hypertension.
Dickinson MG; Schölvinck EH; Boonstra A; Vonk-Noordegraaf A; Snijder RJ; Berger RM
J Heart Lung Transplant; 2009 Mar; 28(3):273-9. PubMed ID: 19285620
[TBL] [Abstract][Full Text] [Related]
31. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
Small M; Piercy J; Pike J; Cerulli A
Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
[TBL] [Abstract][Full Text] [Related]
32. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
Budev MM; Minai OA; Arroliga AC
Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
[TBL] [Abstract][Full Text] [Related]
33. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy.
Ozkan M; Dweik RA; Laskowski D; Arroliga AC; Erzurum SC
Lung; 2001; 179(4):233-43. PubMed ID: 11891614
[TBL] [Abstract][Full Text] [Related]
34. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions.
Scelsi L; Ghio S; Campana C; D'Armini AM; Serio A; Klersy C; Piovella F; Viganò M; Tavazzi L
Ital Heart J; 2004 Aug; 5(8):618-23. PubMed ID: 15554033
[TBL] [Abstract][Full Text] [Related]
35. Two formulations of epoprostenol sodium in the treatment of pulmonary arterial hypertension: EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a phase IV, open-label, randomized study.
Chin KM; Badesch DB; Robbins IM; Tapson VF; Palevsky HI; Kim NH; Kawut SM; Frost A; Benton WW; Lemarie JC; Bodin F; Rubin LJ; McLaughlin V
Am Heart J; 2014 Feb; 167(2):218-225.e1. PubMed ID: 24439983
[TBL] [Abstract][Full Text] [Related]
36. Use of prostacyclin and its analogues in the treatment of cardiovascular disease.
Fink AN; Frishman WH; Azizad M; Agarwal Y
Heart Dis; 1999; 1(1):29-40. PubMed ID: 11720602
[TBL] [Abstract][Full Text] [Related]
37. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.
Preston IR; Klinger JR; Houtches J; Nelson D; Farber HW; Hill NS
Respir Med; 2005 Dec; 99(12):1501-10. PubMed ID: 15890512
[TBL] [Abstract][Full Text] [Related]
38. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol.
Kuhn KP; Byrne DW; Arbogast PG; Doyle TP; Loyd JE; Robbins IM
Am J Respir Crit Care Med; 2003 Feb; 167(4):580-6. PubMed ID: 12446266
[TBL] [Abstract][Full Text] [Related]
39. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
Mathier MA; McDevitt S; Saggar R
J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
[TBL] [Abstract][Full Text] [Related]
40. Inhaled prostacyclin, nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement.
Fattouch K; Sbraga F; Bianco G; Speziale G; Gucciardo M; Sampognaro R; Ruvolo G
J Card Surg; 2005; 20(2):171-6. PubMed ID: 15725144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
